Olverembatinib combined with inotuzumab ozogamicin in Philadelphia chromosome-positive acute lymphoblastic leukemia with multiple relapses: a case report
Relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is difficult to treat, facing a poor prognosis and short overall survival. The usage of tyrosine kinase inhibitor (TKI) and immunotherapy has brought new hope for the treatment of R/R Ph+ ALL for patien...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Chinês |
| Publicat: |
The editorial office of the Journal of Internal Medicine Concepts & Practice
2026-02-01
|
| Col·lecció: | Neike lilun yu shijian |
| Matèries: | |
| Accés en línia: | https://doi.org/10.16138/j.1673-6087.2026.01.08 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|